ReviewEvidence-based complementary and alternative medicine : eCAM2021
Noscapine, an Emerging Medication for Different Diseases: A Mechanistic Review.
Review in Evidence-based complementary and alternative medicine : eCAM, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 51 citations in OpenAlex.
- A Semi-Mechanistic Population Pharmacokinetic Model of Noscapine in Healthy Subjects Considering Hepatic First-Pass Extraction and CYP2C9 Genotypes.Drugs in R&D · 2024Trial
- Review
- Anticonvulsant effects of noscapine against status epilepticus induced by lithium-pilocarpine in rats: involvement of Nrf2/HO-1 and NLRP3 pathways.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Optimizing wound healing: insights from phytochemicals and advanced therapies.Inflammopharmacology · 2025Review
- Investigating the chemo-preventive role of noscapine in lung carcinoma via therapeutic targeting of human aurora kinase B.Molecular and cellular biochemistry · 2025Article
- Phytoactive Molecules and Nanodelivery Approaches for Breast Cancer Treatment: Current and Future Perspectives.Current pharmaceutical biotechnology · 2025Review
- Discovery of drug transporter inhibitors tied to long noncoding RNA in resistant cancer cells; a computational model -in silico- study.Frontiers in immunology · 2025Review
- Developing benzylisoquinoline alkaloid-enriched opium poppy via CRISPR-directed genome editing: A review.BMC plant biology · 2024Review
- Noscapine and Apoptosis in Breast and Other Cancers.International journal of molecular sciences · 2024Review
- A Mechanistic Review on Protective Effects of Mangosteen and its Xanthones Against Hazardous Materials and Toxins.Current neuropharmacology · 2024Review
- Promising approaches for simultaneous enhancement of medicinally significant benzylisoquinoline alkaloids in opium poppy.Frontiers in plant science · 2024Review
- A versatile regulatory toolkit of arabinose-inducible artificial transcription factors for Enterobacteriaceae.Communications biology · 2023Article
- Inhibition of Myeloperoxidase Pro-Fibrotic Effect by Noscapine in Equine Endometrium.International journal of molecular sciences · 2023Article
- Development of 9-(3 Biotech · 2023Article
- Retracted: Noscapine, an Emerging Medication for Different Diseases: A Mechanistic Review.Evidence-based complementary and alternative medicine : eCAM · 2023Article
- Integration of phytotherapy and chemotherapy: Recent advances in anticancer molecular pathways.Iranian journal of basic medical sciences · 2023Review
- Reduced acetylated α-tubulin inFrontiers in neuroscience · 2023Article
- Acetyl-11-Keto-Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Identification of the circRNA-miRNA-mRNA regulatory network in osteoarthritis using bioinformatics analysis.Frontiers in genetics · 2022Article
- Topical Formulation of Noscapine, a Benzylisoquinoline Alkaloid, Ameliorates Imiquimod-Induced Psoriasis-Like Skin Lesions.Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
- Retraction · 2023-12-13Compromised Peer Review · Investigation by Journal/Publisher · Investigation by Third Party · Paper Mill · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Noscapine is a benzylisoquinoline alkaloid isolated from poppy extract, used as an antitussive since the 1950s, and has no addictive or euphoric effects. Various studies have shown that noscapine has excellent anti-inflammatory effects and potentiates the antioxidant defences by inhibiting nitric oxide (NO) metabolites and reactive oxygen species (ROS) levels and increasing total glutathione (GSH). Furthermore, noscapine has indicated antiangiogenic and antimetastatic effects. Noscapine induces apoptosis in many cancerous cell types and provides favourable antitumour activities and inhibitory cell proliferation in solid tumours, even drug-resistant strains, via mitochondrial pathways. Moreover, this compound attenuates the dynamic properties of microtubules and arrests the cell cycle in the G2/M phase. Noscapine can reduce endothelial cell migration in the brain by inhibiting endothelial cell activator interleukin 8 (IL-8). In fact, this study aimed to elaborate on the possible mechanisms of noscapine against different disorders.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.